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Abstract. Old World species of Leishmania typically cause visceral and cutaneous leishmaniasis. Mucosal in-
volvement is typically seen with infection by Leishmania species found in South America, usually after the healing of
cutaneous leishmaniasis. We present ﬁve imported cases of mucosal leishmaniasis caused by OldWorld Mediterranean
Leishmania infantum exclusively affecting the nasal mucosa or vocal cord. In only one case was there a recollection of a
preceding cutaneous lesion compatible with cutaneous Leishmaniasis. Of signiﬁcance was that four out of ﬁve cases
were receiving local corticosteroids for chronic lungdisorders and fourwere systemically immunosuppressed. This report
highlights the importanceof consideringmucosal leishmaniasis in thedifferential diagnosis in thosepresentingwith upper
respiratory tract mucosal lesions with a relevant travel history to the Mediterranean and in whom malignancy has been
excluded.
INTRODUCTION
Leishmaniasis has three main clinical forms: visceral, cu-
taneous, and mucosal disease. Worldwide there is an esti-
mated annual incidence of 1.3 million cases across 98
countrieswith an additional 310million at risk of infection.1 It is
a disease caused by the protozoan parasite Leishmania,
transmitted by the bite of the female sandﬂy. A number of
animals serve as natural reservoirs including domestic and
wild dogs, foxes, wolves, sloths, rats, and mice.2 Human be-
ings are directly involved as a principal reservoir host in two
forms of the disease: visceral leishmaniasis (VL) caused by
Leishmania donovani and cutaneous leishmaniasis (CL)
caused by Leishmania tropica.3
There aremore than 20 species of Leishmania; the resulting
clinical syndrome typically relates to the infecting species.3 In
the Old World, L. donovani (in regions of India, Pakistan,
China, and Africa) and Leishmania infantum (in the Mediter-
ranean Region) typically cause VL.
There have also been reports of VL caused by L. tropica in
theMiddle East and India.4,5 In comparison, Leishmaniamajor
and L. tropica cause CL.
Mucosal leishmaniasis (ML) is a disease largely conﬁned to
South America whereby a small proportion of patients
(1–10%) mainly infected with Leishmania braziliensis and
Leishmania panamensis develop mucous membrane in-
volvement of the nose, and less commonly the oral cavity,
pharynx, and or larynx, months to years after healing of pri-
mary cutaneous lesions.6,7 This report contributes to the
recognition in recent decades that Old World species can
cause localized mucosal disease, contributed to by local or
systemic immunosuppression.8–19
CASES
Case 1.A 72-year-old man, with a past medical history of
Addison’s disease on hydrocortisone, was referred in May
2012 with nasal swelling and unilateral deafness. He had
lived in Spain intermittently for the previous 35 years and
mostly for the preceding 5 years. He gave a history of
lifelong hay fever treated with a corticosteroid nasal spray.
He had also been takingmethotrexate and prednisolone for
rheumatoid arthritis and myelodysplasia for 4 years.
Symptoms began 3 years earlier with nasal congestion.
Two years later he developed a blocked nose associated
with epistaxis and was given a diagnosis of localized anti-
neutrophil cytoplasmic antibodies-negative Wegener’s
Granulomatosis (now renamed granulomatosis with poly-
angiitis). Later that same year he developed visible swelling
and erythema of his nose and unilateral deafness. At the time
of grommet insertion, a biopsy was taken of the local tissue
and this demonstrated evidence of Leishmania amastigotes
and was conﬁrmed with detection of L. donovani complex
DNA by polymerase chain reaction (PCR) (nested PCR-based
schizodeme method).20
He was commenced on a 30-day course of oral miltefo-
sine, 150mg once daily, and the level of immunosuppression
reduced. At the end of the treatment course, his Leishmania
direct agglutination test (DAT) (one in 25,600 [cutoff 1:1,600];
KIT-Biomedical Research, Royal Tropical Institute, Nether-
lands) and rK39 antibody (recombinant kinesin) were posi-
tive. The DAT detects antibodies to L. donovani in the blood
or serum of those infected by means of direct agglutina-
tion.21 The rK39 rapid antibody test detects antibodies to a
protein-encoding gene (K39) found in Leishmania species.22
A bone marrow sample from 2010 was obtained and this did
not have any amastigotes and PCR for Leishmania DNA was
negative. Nine months posttreatment, he had no further fe-
vers and had gained weight. Two years later, biopsies taken
during nasal reconstruction were PCR negative for Leish-
mania DNA.
Case 2. A 69-year-old man was referred with a 30-month
history of a hoarse voice in June 2014. He had been living in
southern Spain for 3–4months over the preceding few years.
He had a past medical history of asthma and bronchiectasis
for which he regularly used a corticosteroid inhaler and
systemic steroids. In December 2013, an irregular left vocal
cord was noted on routine bronchoscopy. Microlaryngoscopy
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in April 2014 demonstrated a ﬁrm cystic area arising from the
surface of the left true vocal cord. Histology of a total excision
biopsy demonstrated numerous Leishmania amastigotes,
conﬁrmedwith detection of L. donovani complex DNA by PCR.
Three months later, a bronchoscopy demonstrated an abnor-
mal trachea with a nodular and cobblestoned appearance
(Figure 1).
At presentation, there was no organomegaly or lymphade-
nopathy and his Leishmania DAT was positive at a low titer of
one in 3,200. A 30-day course of miltefosine was started
duringwhich time the inhaled prednisolonewas discontinued.
One year after completing treatment, he had had no evidence
of Leishmania recurrence.
Case 3. A 56-year-old man was referred in July 2011 with a
2-year history of inﬂammatory swellings of the nasal lining
causing nasal block. Travel history included annual visits to
Greece for the previous 14 years.
His symptoms began 7 years prior with sinusitis and difﬁ-
culty breathing. He had a past medical history of rheumatoid
arthritis for which he was taking methotrexate, adalimumab,
and rituximab. Initial biopsies in 2009 demonstrated a lym-
phocytic inﬁltrate.On thebasis that hehadpossibly hada local
form of granulomatosis with polyangiitis, he was given corti-
costeroids. After this, his symptoms worsened with nasal
swelling, blockage, and ulceration. A further biopsy 2 years
later detected L. donovani complex DNA by PCR. At pre-
sentation, he had massive swelling and erythema of his nose
and crusting of the nasal passages with minimal lymphade-
nopathy and a palpable splenic tip (Figure 2). A Leishmania
DAT was negative but the K39 antibody was positive. He was
started on once daily intravenous sodium stibogluconate
(SSG) for 28 days. During treatment, his immunosuppres-
sants were stopped temporarily. Twelve months later, his
nose lesion had healed completely and hewas recurrence free
3 years later.
Case 4. A 60-yearold woman was referred in May 2015
with a 4 month history of a hoarse voice and occasional
fever. She recalled a previous skin lesion affecting the neck
which had spontaneously healed which may have been
localized CL. She had lived in southern Spain for the past
7 years. She had a 10-year history of asthma, for which she
took regular corticosteroid inhalers and short courses of
prednisolone.
Laryngoscopy in April 2015 demonstrated left vocal cord
palsy with granulomatous inﬂammation of both false cords.
Histology demonstrated numerous amastigotes of Leish-
mania, conﬁrmed with detection of L. donovani complex DNA
by PCR. LeishmaniaDATwas positive at a titer of 1 in 102,400
and K39 antibody was positive. Twelve months after a 30-day
course of miltefosine, her hoarse voice had resolved with no
evidence of vocal cord recurrence on endoscopy.
Case 5. A 54-year-old woman was referred in February
2016 with a 3-month history of a hoarse voice, cough, and
choking episodes. She had a history of a previous crusted
ulcer on her leg, which spontaneously healed 8 years prior to
presentation. She had lived for periods in a rural area of
Greece for the previous 11 years. She has had a pastmedical
history of emphysema for 15 years for which she had re-
ceived numerous courses of mainly inhaled but also sys-
temic corticosteroids.
FIGURE 1. Case 2. Nodular appearance of trachea on bronchos-
copy, due to mucosal leishmaniasis. This ﬁgure appears in color at
www.ajtmh.org.
FIGURE 2. Case 3. Granulomatous lesions of mucosal leishmani-
asis of nasal passages and surrounding skin. This ﬁgure appears in
color at www.ajtmh.org.
FIGURE 3. Case 5. Histology of vocal cord biopsy demonstrating
Leishmania amastigotes. This ﬁgure appears in color at www.ajtmh.
org.
OLD WORLD MUCOSAL LEISHMANIASIS 1117
Nasendoscopy in February 2016 demonstrated granulo-
matous lesionsaffecting the vocal cords.Histologyof abiopsy
demonstrated amastigotes of Leishmania (Figure 3), con-
ﬁrmed with detection of L. donovani complex DNA by PCR.
Leishmania DAT was negative and K39 antibody weakly
positive. She was treated with a 30-day course of miltefosine.
She experienced severe adverse effects during the course
including vomiting, abdominal pain, and headaches. Two
weeks after completion of treatment, her voice, swallowing,
and exercise tolerance had improved.
DISCUSSION
Over the past three decades, and increasingly so more
recently, it has been recognized that ML can exist outside
the South American continent where clinical presentations
are less well deﬁned.8 In comparison to the destructive
predominantly nasal (90%) mucosal lesions of New World
ML, Old World ML appears to commonly affect other areas
such as the buccal mucosa as well as the pharynx and
larynx.7,10–16,23 Immunocompromise, systemic or local,
appears to be a signiﬁcant risk factor making L. infantum an
opportunistic pathogen in this setting.8,9,24 Localizedmucosal
disease can be either accompanied or preceded by CL or
VL in Old World ML. In only one case could the patient recall
a preceding lesion of CL. In three of ﬁve cases presented
here, the high DAT titers and/or positive K39 antibody was
likely to represent a systemic response to infection.
Leishmania donovani complex was detected by PCR of
affected tissue. In all ﬁve cases, the likely causative species
was L. infantum given the travel history and geographical
distribution of L. infantum in the Mediterranean with the do-
mestic dog serving as the main reservoir host.2
The route by which Leishmania protozoa localize to mu-
cous membranes in Old World ML is unclear. It has been
suggested that it is either from hematogenous spread from a
distant initial inoculation or from direct mucosal injection of
parasites.24,25 Evidence suggests that the former explana-
tion is more plausible, considering the high rates of asymp-
tomatic carriage of L. infantum in theMediterranean region.26
Important, however, to the development of disease is the fact
that four of the ﬁve cases presented here were taking inhaled
corticosteroids. This has previously been suggested to be
a risk factor for developing ML, along with tobacco smoke
and upper respiratory tract diseases, by inducing localized
mucosal immunosuppression.8–10,24 Four of the ﬁve were
also signiﬁcantly systemically immunosuppressed, due to
corticosteroids or other immunosuppressive drugs, which is
also a recognized risk factor for the development of ML (see
Table 1 for summary of ﬁve cases).24,27 Cessation of immu-
nosuppressants during therapy is therefore likely to increase
the chances of cure and prevent disease relapse.
Pentavalent antimonials such as SSG, administered in-
travenously for 28 days, are recommended by theWorldHealth
Organization for the treatment of South American ML.28 Alter-
natives include amphotericin B (deoxycholate or a lipid formu-
lation), paramomycin, and pentamidine.29 The mainstay of
treatment of Mediterranean leishmaniasis has also been the
antimonials with good reported cure rates.8 However, due to
signiﬁcant toxicity issues and the need for potential hospitali-
zation to administer these drugs, oral miltefosine (150 mg once
daily), an agent used for the treatment of VL acquired in India,
could be a highly effective alternative for the treatment of
mucosal disease caused by L. infantum in an outpatient
setting. Three treatment studies of Old World CL caused by
L. major have demonstrated a mean cure rate of 93% with
miltefosine.30–32 Evidence for its use in the treatment of CL
caused by L. tropica and L. donovani is limited to a small
number of case reports. A recent case series and literature
review of 24 patients with Old World CL as well as ML has
demonstrated good cure rates with miltefosine, particularly in
the absence of immunoscompromise.33 Most studies evalu-
ating treatment lengths and dosing regimens have demon-
strated that a 28-day course is sufﬁcient in the treatment of VL
and Old World CL but the duration of treatment in those with
immunocompromise, human immunodeﬁciency virus (HIV) or
other etiologies, has not yet been established.34–36 The ra-
tionale for a 30-day course used in the patients presented here
is based on limited published evidence of encouraging cure
rates inHIV-coinfected patients given an initial median duration
of treatmentof30days.37 In linewith reportedcure ratesof75%
with miltefosine in Bolivian ML, four cases treated here were
successfully treated without the need for hospitalization.38,39
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TABLE 1
Summary of ﬁve cases of Old World ML
Case 1 Case 2 Case 3 Case 4 Case 5
Site of ML Nasal mucosa and middle ear Vocal cord Nasal mucosa Vocal cord Vocal cord
Country of acquisition Spain Spain Greece Spain Greece
Signiﬁcant conditions Rheumatoid arthritis
Myelodysplasia Allergic rhinitis
Asthma Bronchiectasis Rheumatoid arthritis Asthma Emphysema
Local immunosuppression Yes Yes No Yes Yes
Systemic immunosuppression:
Corticosteroids Yes Yes Yes Yes Yes
Biologic agents No No Yes—adalimumab,
rituximab
No No
Other immunosuppression Yes - methotrexate No Yes—methotrexate No No
Treatment (days) Miltefosine (30) Miltefosine (30) SSG (28) Miltefosine (30) Miltefosine (30)
Recurrence free (months) 24 12 36 12 1
ML = mucosal leishmaniasis; SSG = sodium stibogluconate.
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